Bilateral Symmetric Thalamic Metastasis in a Patient with Small Cell Lung Cancer
Journal Title: Cancer Studies & Molecular Medicine – Open Journal - Year 2018, Vol 4, Issue 1
Abstract
A 68-year old woman was referred to our hospital because of dry cough with persistent numbness in the extremities. Chest roentgenogram showed right hilar tumor with mediastinal lymphnode and brain magnetic resonance imaging (MRI) revealed multiple tiny nodules. After performing the transbronchial needle aspiration obtained from subcarinal lymphnode, she was diagnosed with small cell lung cancer (SCLC) accompanied by multiple brain metastasis (clinical stage IV: T4N3M1). After completion of four cycles of chemotherapy, the size of lung lesion was regressed together with complete resolution of brain lesions, and she discharged uneventfully. However, her numbness was remained. Four months later, she was hospitalized again for severe numbness in her trunk and extremities. Brain MRI (contrast-enhanced T1-weighted image) demonstrated new symmetric metastatic lesions in bilateral thalamus (Figure A and B) as well as left putamen. Another two months later, numbness exacerbated and spread from the top to toe with the growing of primary and bilateral thalamic metastatic lesions on computed tomography (CT) (Figure C and D). In spite of whole-brain irradiation, she had suffered from severe numbness, and died of obstructive pneumonia. To our knowledge, this is the first case of bilateral symmetric thalamic metastasis in SCLC with refractory numbness over the whole body.
Authors and Affiliations
Takeshi Saraya
Keywords
Related Articles
- EP ID EP559118
- DOI 10.17140/CSMMOJ-4-123
- Views 116
- Downloads 0
Dysadherin: A Novel Oncogenic Molecular Biomarker in Oesophageal Cancer
Dysadherin or FXYD5 is a transmembrane glycoprotein, identified for the first time in 2002 by a team of Japanese researchers.1 Although, it is generally accepted that most of its action is derived from the increased maxi...
Is it Time to Start Using Mitochondrial DNA Copy Number as an Indicator of Health and Diseases?
Clinical biochemistry and pathology have contributed too many assays for diagnosis and prognosis of human health and diseases. Bedside biochemistry has revolutionized modern medicine and the invention of new generation b...
Potential of Molecular Imaging to Advance Molecular Medicine
Molecular imaging is a technology that allows for non-invasive interrogation of physiological and biochemical processes in the body. Over the years, the use of Molecular Imaging is on the rise, especially towards diagnos...
Regulation in Cell Cycle via p53 and PTEN Tumor Suppressors
One of the target effectors of p53 transcription factor is the Phosphatase and Tensin homologue deleted on chromosome 10 (PTEN) which has protein phosphatase activity and lipid phosphatase activity that antagonizes PI3K...
Long Term, Low Dose Genistein decreases Stem Cell Populations and Sensitizes Inflammatory Breast Cancer Cell Lines to Radiation
Local recurrence in inflammatory breast cancer is common and is associated with poor prognosis. Recurrence is driven by a small population of radioresistant breast cancer cells that have stem-like properties. Previous st...